India-Specific Sickle Cell Severity Score (ISS1 and ISS2): CSIR-CCMB’s Step Towards Precision Public Health

Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, have developed an India-specific disease severity score for sickle cell anaemia (SCA). The tool is built on clinical data from Indian children, and it aims to help doctors predict how severely the disease will affect a patient.

The development matters because international scoring systems were designed mostly around African cohorts and do not match the clinical profile of Indian patients. Indian patients are said to have a milder disease profile than many African populations. The study was led by Giriraj R. Chandak, physician-scientist and Sir J.C. Bose Fellow at CSIR-CCMB, together with colleagues including Suraj S. Nongmaithem and Dipty Jain.

For aspirants, this connects genomics, public health policy and the National Sickle Cell Anaemia Elimination Mission, a recurring theme in GS-III science and technology and GS-II health.

Background and Context

SCA is an inherited blood disorder caused by a mutation in the beta globin gene, which produces abnormal haemoglobin that makes red blood cells assume a sickle shape. The consequences are anaemia, painful episodes, organ damage and complications. India has among the highest burdens in the world, concentrated in central and western tribal belts.

Five Important Key Points

• The revised model, ISS1, improves clinical assessment concordance to nearly 83%.
• A second version, ISS2, replaces laboratory measurements with easily observable clinical indicators and reaches about 85% concordance.
• ISS2 allows clinicians to decide management without extensive laboratory investigations, which suits resource-limited settings.
• The tool was developed from clinical data on Indian children because existing scores do not reflect India’s clinical profile.
• The National Sickle Cell Anaemia Elimination Mission, launched in 2023, targets elimination as a public health problem by 2047.

The Science Behind Severity Scoring

Severity in SCA varies widely even among patients with the same mutation. Genetic modifiers such as higher fetal haemoglobin levels and co-inherited alpha-thalassaemia influence outcomes, and particular haplotypes are associated with milder disease. A severity score converts clinical history, such as frequency of pain crises, hospitalisations and transfusions, into a standardised number, so that treatment intensity, including hydroxyurea dosing and transfusion planning, can be matched to need.

Policy Framework

The National Sickle Cell Anaemia Elimination Mission was launched on 1 July 2023 with the aim of screening a large population aged 0 to 40 in high-prevalence districts across multiple States, providing counselling and care. The Rights of Persons with Disabilities Act, 2016 recognises sickle cell disease as a specified disability, which entitles patients to benefits. Hydroxyurea is available under the public system, and the Indian Council of Medical Research (ICMR) and CSIR have pursued gene-therapy research for the disease.

Economic and Health-System Implications

Severity scores can improve resource allocation. Patients with a milder profile may need less intensive monitoring, while high-risk patients can be prioritised for hydroxyurea, transfusion programmes and, eventually, curative therapies. ISS2’s reliance on clinical indicators lowers costs and can be used at primary health centres, aligned with Ayushman Bharat Health and Wellness Centres.

Governance and Institutional Issues

India’s SCA response has to cope with fragmented care, limited blood-bank capacity and weak follow-up in tribal districts. Data quality is another problem, since the new score is built on paediatric data and must be validated across adults, States and genotypes. Genetic screening also raises privacy and stigma concerns, especially around marriage counselling.

Social Impact

SCA disproportionately affects Scheduled Tribes and other marginalised groups with limited access to healthcare. Stigma around a hereditary condition and the economic cost of repeated hospitalisation reinforce poverty. A tailored tool helps clinicians avoid both under-treatment and over-treatment.

Comparative Perspective

In the United States, newborn screening for sickle cell disease is universal and hydroxyurea is standard care. Nigeria carries the largest global burden, and Ghana and other African states have built newborn-screening programmes. Gene therapies have been approved in the United States and United Kingdom but remain very expensive, which is why India has pursued indigenous gene-editing research through CSIR institutions.

Bihar Connection

Bihar is not among the highest-burden States, but sickle cell cases occur in pockets, and Bihar’s border with Jharkhand and tribal communities in the region merit attention. The State’s health department needs district-level screening data, and the severity score can aid clinicians at medical colleges such as those in Patna. Bihar also has a large pool of Anaemia-affected populations, so strengthening screening and referral for haemoglobinopathies alongside iron-deficiency programmes would be sensible.

Way Forward

• Validate ISS1 and ISS2 in adult and multi-State cohorts before national adoption.
• Integrate ISS2 into Ayushman Bharat primary-care protocols and the National Health Mission.
• Expand newborn screening and ensure uninterrupted hydroxyurea supply.
• Build secure, consent-based genetic data governance to prevent stigma.
• Invest in indigenous gene therapy and bone-marrow transplant capacity at lower cost.

Relevance for UPSC and SSC Examinations

UPSC: GS-III: biotechnology, genomics, indigenous technology. GS-II: health policy and vulnerable sections. Essay: science for inclusive development.

SSC: CSIR, CCMB, sickle cell anaemia, haemoglobin, National Sickle Cell Anaemia Elimination Mission, RPwD Act 2016.

Key terms: ISS1, ISS2, beta globin, hydroxyurea, fetal haemoglobin, haemoglobinopathy, concordance, precision medicine.